Literature DB >> 29856021

Generating Excitotoxic Lesion Models of Huntington's Disease.

Mariah J Lelos1, Stephen B Dunnett2.   

Abstract

In Huntington's disease (HD), the medium spiny projection neurons of the neostriatum degenerate early in the course of the disease. While genetic mutant models of HD provide an excellent resource for studying the molecular and cellular effects of the inherited polyQ huntingtin mutation, they do not typically present with overt atrophy of the basal ganglia, despite this being a major pathophysiological hallmark of the disease. By contrast, excitotoxic lesion models, which use quinolinic acid to specifically target the striatal projection neurons, are employed to study the functional consequences of striatal atrophy and to investigate potential therapeutic interventions that target the neuronal degeneration. This chapter provides a detailed guide to the generation of excitotoxic lesion models of HD in rats.

Entities:  

Keywords:  Cognition; Excitotoxic lesion; Huntington’s disease; Motor; Neurotoxin; Quinolinic acid; Striatum

Mesh:

Substances:

Year:  2018        PMID: 29856021     DOI: 10.1007/978-1-4939-7825-0_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.

Authors:  Majken B Thomsen; Jan Jacobsen; Thea P Lillethorup; Anna C Schacht; Mette Simonsen; Marina Romero-Ramos; David J Brooks; Anne M Landau
Journal:  J Cereb Blood Flow Metab       Date:  2020-06-14       Impact factor: 6.200

2.  Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioral and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington's disease.

Authors:  Yongwoo Yoon; Hyun Sook Kim; Iksoo Jeon; Jeong-Eun Noh; Hyun Jung Park; Suji Lee; In-Hyun Park; Lara Stevanato; Caroline Hicks; Randolph Corteling; Roger A Barker; John D Sinden; Jihwan Song
Journal:  Stem Cells       Date:  2020-05-06       Impact factor: 6.277

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.